首页> 美国卫生研究院文献>Pulmonary Circulation >Anagrelide-induced pulmonary arterial hypertension: a rare case of drug-induced pulmonary arterial hypertension
【2h】

Anagrelide-induced pulmonary arterial hypertension: a rare case of drug-induced pulmonary arterial hypertension

机译:阿那格雷利特诱发的肺动脉高压:罕见的药物诱发的肺动脉高压病例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Pulmonary arterial hypertension can be associated with exposure to certain drugs or toxins. However, only a few cases of drug-induced pulmonary arterial hypertension have been previously reported. Anagrelide is an oral imidazoquinazoline agent that is prescribed for reducing elevated platelet counts in patients with myeloproliferative disorders. We report the case of a 70-year-old female patient who developed pulmonary arterial hypertension after taking anagrelide for the treatment of polycythemia vera. Pulmonary arterial hypertension promptly improved after the discontinuation of anagrelide. Anagrelide-induced pulmonary arterial hypertension is a very rare disease, and our case shows that it might be reversible.
机译:肺动脉高压可能与某些药物或毒素的接触有关。但是,以前仅报道了几例药物诱发的肺动脉高压。阿那格雷(Anagrelide)是一种口服咪唑并喹唑啉类药物,开处方用于减少骨髓增生性疾病患者的血小板计数升高。我们报告了一例70岁的女性患者,该患者在服用阿那格雷利治疗真性红细胞增多症后发展为肺动脉高压。终止阿那格雷治疗后,肺动脉高压立即得到改善。阿那格雷利特诱发的肺动脉高压是一种非常罕见的疾病,我们的病例表明它可能是可逆的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号